US48115J1097 - Common Stock
JOURNEY MEDICAL CORP
NASDAQ:DERM (12/6/2024, 8:00:01 PM)
After market: 5.22 -0.13 (-2.43%)5.35
-0.13 (-2.37%)
Journey Medical Corp. is a commercial-stage pharmaceutical company, which focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company is headquartered in Scottsdale, Arizona and currently employs 58 full-time employees. The company went IPO on 2021-11-12. The firm is focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes seven branded and two authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved by the United States Food and Drug Administration (FDA) for sale, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox and Luxamend. The company sells two authorized generic products, including sulconazole nitrate cream and solution and doxycycline hyclate immediate release 50mg tablets. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne.
JOURNEY MEDICAL CORP
9237 E Via De Ventura Blvd., Suite 105, Suite 105
Scottsdale ARIZONA 94025
P: 14804346670
CEO: Thomas G. Wiggans
Employees: 41
Website: https://journeymedicalcorp.com/
Let's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session.
U.S. FDA approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of inflammatory lesions of rosacea in adults;...
Journey Medical to host investor conference call on Monday, November 4, 2024, at 8:30 a.m. E.T....
Poster Presented on Dermal and Systemic Pharmacokinetics of Oral DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) versus Oral...
SCOTTSDALE, Ariz., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage...
Here you can normally see the latest stock twits on DERM, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: